JP2021113206A5 - - Google Patents

Download PDF

Info

Publication number
JP2021113206A5
JP2021113206A5 JP2021068923A JP2021068923A JP2021113206A5 JP 2021113206 A5 JP2021113206 A5 JP 2021113206A5 JP 2021068923 A JP2021068923 A JP 2021068923A JP 2021068923 A JP2021068923 A JP 2021068923A JP 2021113206 A5 JP2021113206 A5 JP 2021113206A5
Authority
JP
Japan
Prior art keywords
type
lyophilized preparation
diffraction pattern
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021068923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021113206A (ja
JP7201732B2 (ja
Filing date
Publication date
Priority claimed from JP2018535283A external-priority patent/JP6871256B2/ja
Application filed filed Critical
Publication of JP2021113206A publication Critical patent/JP2021113206A/ja
Publication of JP2021113206A5 publication Critical patent/JP2021113206A5/ja
Application granted granted Critical
Publication of JP7201732B2 publication Critical patent/JP7201732B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021068923A 2016-01-08 2021-04-15 2-(4-クロロフェニル)-n-((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-イル)メチル)-2,2-ジフルオロアセトアミドの製剤 Active JP7201732B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276756P 2016-01-08 2016-01-08
US62/276,756 2016-01-08
JP2018535283A JP6871256B2 (ja) 2016-01-08 2017-01-06 2−(4−クロロフェニル)−n−((2−(2,6−ジオキソピペリジン−3−イル)−1−オキソイソインドリン−5−イル)メチル)−2,2−ジフルオロアセトアミドの製剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018535283A Division JP6871256B2 (ja) 2016-01-08 2017-01-06 2−(4−クロロフェニル)−n−((2−(2,6−ジオキソピペリジン−3−イル)−1−オキソイソインドリン−5−イル)メチル)−2,2−ジフルオロアセトアミドの製剤

Publications (3)

Publication Number Publication Date
JP2021113206A JP2021113206A (ja) 2021-08-05
JP2021113206A5 true JP2021113206A5 (cg-RX-API-DMAC7.html) 2021-09-24
JP7201732B2 JP7201732B2 (ja) 2023-01-10

Family

ID=59273934

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018535283A Active JP6871256B2 (ja) 2016-01-08 2017-01-06 2−(4−クロロフェニル)−n−((2−(2,6−ジオキソピペリジン−3−イル)−1−オキソイソインドリン−5−イル)メチル)−2,2−ジフルオロアセトアミドの製剤
JP2021068923A Active JP7201732B2 (ja) 2016-01-08 2021-04-15 2-(4-クロロフェニル)-n-((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-イル)メチル)-2,2-ジフルオロアセトアミドの製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018535283A Active JP6871256B2 (ja) 2016-01-08 2017-01-06 2−(4−クロロフェニル)−n−((2−(2,6−ジオキソピペリジン−3−イル)−1−オキソイソインドリン−5−イル)メチル)−2,2−ジフルオロアセトアミドの製剤

Country Status (19)

Country Link
US (4) US10052315B2 (cg-RX-API-DMAC7.html)
EP (2) EP4275707A3 (cg-RX-API-DMAC7.html)
JP (2) JP6871256B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180100565A (cg-RX-API-DMAC7.html)
CN (2) CN113633634A (cg-RX-API-DMAC7.html)
AU (2) AU2017205167B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018013884A2 (cg-RX-API-DMAC7.html)
CA (1) CA3010797C (cg-RX-API-DMAC7.html)
CL (1) CL2018001830A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018008305A2 (cg-RX-API-DMAC7.html)
EA (1) EA037508B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP18051143A (cg-RX-API-DMAC7.html)
ES (1) ES2956767T3 (cg-RX-API-DMAC7.html)
IL (1) IL260403B (cg-RX-API-DMAC7.html)
MX (1) MX382150B (cg-RX-API-DMAC7.html)
SA (1) SA518391983B1 (cg-RX-API-DMAC7.html)
SG (2) SG10202007913WA (cg-RX-API-DMAC7.html)
WO (1) WO2017120437A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201804482B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
US10052315B2 (en) * 2016-01-08 2018-08-21 Celgene Corporation Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
EP3399980B1 (en) 2016-01-08 2025-07-16 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
SG11201809501PA (en) 2016-06-06 2018-12-28 Celgene Corp Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
EP4201399A3 (en) * 2017-06-30 2023-08-09 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
EA202191833A1 (ru) * 2018-12-31 2021-10-11 Селджин Корпорейшн Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида
CA3157196A1 (en) * 2019-11-05 2021-05-14 Celgene Corporation Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide
IL293481A (en) 2019-12-06 2022-08-01 Celgene Corp Processes for the preparation of 2-(4-chlorophenyl)-n-((2-(2,6-dioxypyridin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
CN100457098C (zh) * 2006-12-20 2009-02-04 南京科源医药技术有限公司 甲磺酸萘莫司他冻干粉针剂及其制备方法
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
CN101224296A (zh) * 2008-02-01 2008-07-23 山东先声麦得津生物制药有限公司 一种稳定的重组人血管内皮抑制素制剂及其制备工艺
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
CA2957226C (en) * 2008-10-29 2018-08-14 Celgene Corporation Isoindoline compounds for use in the treatment of cancer
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EP2699091B1 (en) * 2011-03-28 2017-06-21 DeuteRx, LLC 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
US8974811B2 (en) * 2013-03-14 2015-03-10 Hikma Pharmaceuticals Stabilized pharmaceutical formulations comprising antineoplastic compounds
WO2014179661A1 (en) 2013-05-03 2014-11-06 Celgene Corporation Methods for treating cancer using combination therapy
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
US10052315B2 (en) * 2016-01-08 2018-08-21 Celgene Corporation Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
TWI782395B (zh) 2016-01-08 2022-11-01 美商西建公司 抗增生化合物,及其醫藥組合物及用途
CA3010794A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
JP2019011495A (ja) 2017-06-30 2019-01-24 株式会社Uacj押出加工 熱交換器に配管部材を接続するためのアルミニウム合金製コネクタ及び該コネクタを備える熱交換器接続用配管部材、並びにこれらの製造方法
EA202191833A1 (ru) 2018-12-31 2021-10-11 Селджин Корпорейшн Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида
CA3157196A1 (en) 2019-11-05 2021-05-14 Celgene Corporation Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide

Similar Documents

Publication Publication Date Title
JP2019501191A5 (cg-RX-API-DMAC7.html)
JP2019131596A5 (cg-RX-API-DMAC7.html)
FI3644999T3 (fi) 2-(4-kloorifenyyli)-n-((2-(2,6-dioksopiperidin-3-yyli)-1-oksoisoindolin-5-yyli)metyyli)-2,2-difluoriasetamidin koostumukset ja menetelmät sen käyttämiseksi
JP7332293B2 (ja) バルリチニブおよび抗癌剤を含んでなる併用療法
KR101434324B1 (ko) 피모벤단과 사이클로덱스트린의 복합물을 포함하는 액상 제제
JP2020518599A5 (cg-RX-API-DMAC7.html)
JP2019502708A5 (cg-RX-API-DMAC7.html)
US20090093467A1 (en) Therapeutic compositions and methods
JP2006523216A5 (cg-RX-API-DMAC7.html)
JP6734971B2 (ja) がん治療薬
CN101743004A (zh) 治疗用组合物及其用途
JP2023530316A5 (cg-RX-API-DMAC7.html)
JP2016518398A (ja) 低用量医薬組成物
JP2022541341A5 (cg-RX-API-DMAC7.html)
JP7526175B2 (ja) Bcl-2阻害剤のシクロデキストリンに基づく製剤
Trarbach et al. Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours
NZ805649A (en) Aqueous formulation comprising 1-(4-{ [4-(dimethylamino)piperidin-1-yl]carbonyl} phenyl)-3- [4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
JP2021511344A5 (cg-RX-API-DMAC7.html)
TW202337469A (zh) 治療小細胞肺癌之方法
JP2019142823A5 (cg-RX-API-DMAC7.html)
JP2017193591A (ja) 腫瘍細胞選択的抗がん剤
CN1477977A (zh) N-(甲基乙基氨基羰基)-4-(3-甲基苯基氨基)-3-吡啶基磺酰胺及环状低聚糖的组合物
JP2020536126A (ja) 経口ベンダムスチン製剤
JP2022550037A (ja) 局所進行性扁平上皮癌を有する患者の治療のための投与レジメン
CN1302777C (zh) 包括取代的丙烯酰偏端霉素衍生物和放射治疗的抗肿瘤联合疗法